Larry L. Wood Sells 18,960 Shares of Edwards Lifesciences Corporation (EW) Stock

Edwards Lifesciences Corporation (NYSE:EW) VP Larry L. Wood sold 18,960 shares of the company’s stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $104.76, for a total value of $1,986,249.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Larry L. Wood also recently made the following trade(s):

  • On Friday, September 15th, Larry L. Wood sold 18,960 shares of Edwards Lifesciences Corporation stock. The stock was sold at an average price of $112.58, for a total value of $2,134,516.80.
  • On Wednesday, August 30th, Larry L. Wood sold 18,960 shares of Edwards Lifesciences Corporation stock. The stock was sold at an average price of $111.81, for a total value of $2,119,917.60.

Shares of Edwards Lifesciences Corporation (NYSE:EW) traded up $2.12 on Thursday, hitting $107.10. The stock had a trading volume of 933,774 shares, compared to its average volume of 1,638,349. Edwards Lifesciences Corporation has a 52 week low of $81.12 and a 52 week high of $121.45. The company has a quick ratio of 2.76, a current ratio of 3.49 and a debt-to-equity ratio of 0.33. The company has a market capitalization of $22,660.00, a P/E ratio of 29.13, a price-to-earnings-growth ratio of 1.88 and a beta of 0.46.

Edwards Lifesciences Corporation (NYSE:EW) last released its earnings results on Tuesday, October 24th. The medical research company reported $0.84 EPS for the quarter, missing the consensus estimate of $0.86 by ($0.02). Edwards Lifesciences Corporation had a return on equity of 27.22% and a net margin of 22.47%. The business had revenue of $821.50 million for the quarter, compared to analyst estimates of $833.85 million. During the same period in the prior year, the business earned $0.68 EPS. The company’s revenue for the quarter was up 11.1% on a year-over-year basis. research analysts predict that Edwards Lifesciences Corporation will post 3.75 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this article on another site, it was stolen and reposted in violation of US & international copyright & trademark law. The legal version of this article can be viewed at https://ledgergazette.com/2017/11/16/larry-l-wood-sells-18960-shares-of-edwards-lifesciences-corporation-ew-stock-2.html.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Belpointe Asset Management LLC acquired a new stake in Edwards Lifesciences Corporation during the third quarter worth approximately $354,000. IFM Investors Pty Ltd acquired a new stake in Edwards Lifesciences Corporation during the third quarter worth approximately $637,000. Dana Investment Advisors Inc. grew its stake in Edwards Lifesciences Corporation by 772.9% during the third quarter. Dana Investment Advisors Inc. now owns 27,462 shares of the medical research company’s stock worth $3,002,000 after purchasing an additional 24,316 shares during the period. Sterling Capital Management LLC grew its stake in Edwards Lifesciences Corporation by 6.2% during the third quarter. Sterling Capital Management LLC now owns 25,351 shares of the medical research company’s stock worth $2,771,000 after purchasing an additional 1,471 shares during the period. Finally, DF Dent & Co. Inc. grew its stake in Edwards Lifesciences Corporation by 7.4% during the third quarter. DF Dent & Co. Inc. now owns 13,431 shares of the medical research company’s stock worth $1,468,000 after purchasing an additional 925 shares during the period. 82.17% of the stock is owned by institutional investors and hedge funds.

Several research firms have recently issued reports on EW. BidaskClub lowered Edwards Lifesciences Corporation from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 19th. Cowen and Company restated an “outperform” rating and set a $135.00 price objective (up from $130.00) on shares of Edwards Lifesciences Corporation in a research report on Thursday, July 27th. Barclays PLC upped their price objective on Edwards Lifesciences Corporation from $108.00 to $120.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 27th. Stifel Nicolaus restated a “buy” rating and set a $130.00 price objective (up from $118.00) on shares of Edwards Lifesciences Corporation in a research report on Thursday, July 27th. Finally, Bank of America Corporation upped their price objective on Edwards Lifesciences Corporation from $140.00 to $150.00 and gave the stock a “buy” rating in a research report on Thursday, July 27th. Seven equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $125.17.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Insider Buying and Selling by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply